Eisai, Inc., Announces the Availability of Extended-Release Lorcaserin HCl
Eisai, Inc., is pleased to announce the availability of extended-release lorcaserin HCl, which is now available via prescription to some patients. The new formulation will offer patients a once-daily dosing option that may help them achieve and maintain weight loss. BELVIQ XR® (lorcaserin HCl) CIV is a 20 mg tablet proven to be slowly absorbed in the body and last throughout the day. For more information about BELVIQ XR, including important safety information, view the press release or visit the website.
|
 |
KVK Tech Announces FDA Approval of Lomaira
Last week, the U.S. Food and Drug Administration (FDA) approved Lomaira. Lomaira (phentermine hydrochloride USP) is an 8 mg tablet CIV, which is a low-cost, low-dose prescription medicine used for weight reduction in adults with at least one weight-related condition, such as high blood pressure or type 2 diabetes. To learn more, view the full press release or visit the website.
|
|
Download the Free Pediatric Obesity Algorithm
During Overcoming Obesity 2016, we released the brand new Pediatric Obesity Algorithm! The Pediatric Obesity Algorithm is a tool to educate clinicians and help them understand and treat childhood obesity. It was developed by practicing pediatricians and clinicians who treat obesity in infants, children, and adolescents. All clinicians can use the Pediatric Obesity Algorithm as a resource when making treatment recommendations or when referring patients to specialists or pediatric weight-management centers. Download the free Pediatric Obesity Algorithm online now.
|
|
Apply to Join a Committee by Friday
The deadline to apply to join a committee is Friday, Oct. 7. Get more involved in OMA by joining a committee, and get to know other members while collaborating on projects and gaining leadership experience. Join the organizational outreach committee to engage other professional organizations to increase awareness of obesity medicine. Join the marketing-communication committee to increase awareness and recognition of OMA and the field of obesity medicine among medical professionals. Or, join another committee that interests you:
- Advocacy Committee
- CME Overview Committee
- Marketing-Communication Committee
- Membership Committee
- NP and PA Committee
- Obesity Algorithm® Committee
- Organizational Outreach Committee
- OTF Development Committee
- OTF Marketing-Communication Committee
- OTF Research Committee
- Pediatric Committee
|
 Participate in World Obesity Day on Oct. 11
World Obesity Day aims to stimulate and support practical actions that will help reverse the global obesity crisis. The theme of this year's World Obesity Day is ending childhood obesity.
The prevalence of infant, childhood, and adolescent obesity is rising around the world. Obesity negatively impacts a child's immediate and long-term health, educational attainment, and quality of life. You can support and participate in this year's World Obesity Day on Oct. 11 with free resources from the World Obesity Federation.
|
 Congratulations to Our Overcoming Obesity 2016 OMA Go! Winner
Congratulations to Dr. Kashif Anwar for winning the OMA Go! game at Overcoming Obesity 2016! Dr. Anwar won by playing OMA Go! on the mobile app and completing the most challenges during the conference. Dr. Anwar won the grand prize - a $500 gift card.
|
Obesity Treatment Foundation
|
 Thank You for Supporting the Obesity Treatment Foundation
Thank you to everyone who supported the Obesity Treatment Foundation's programs at Overcoming Obesity 2016! We raised $7,316 during the conference and reception, which puts us closer to meeting our fundraising goal for this year. So far in 2016, we've raised a total of $93,218, which supports research, education, and awareness in the field of obesity medicine. Donate now to help us raise $33,072 and reach our 2016 goal!
|
 Congratulations to Dr. Susan Wolver, Our 2016 Grant Winner
The winner of the $15,000 OTF research grant was announced at Overcoming Obesity 2016. Congratulations to Susan Wolver, MD, FACP, Dipl. ABOM, whose project is titled, "Does a Low-carbohydrate Ketogenic Diet Reduce Liver Fat and Liver Stiffness in Patients with Obesity?" We look forward to working with Dr. Wolver and seeing the results of her study at an upcoming conference. Congratulations, Dr. Wolver!
|
|
|
|
Executive Director
Sponsorships and Exhibits Manager
Operations Manager
Executive Director of the Obesity Treatment Foundation
|
|
101 University Blvd.,
Suite 330
Denver, CO 80206
|
|
|
Obesity and Management of Weight Loss: Clinical Decisions
Yeh, J. S., Kushner, R. F., Schiff, G. D. JAMA, 2016.
This article addresses two different approaches for a patient who is considering medication for weight loss. Based on the case provided in the article, which of the following treatment options would you recommend for this patient?
- Start a lifestyle modification program and prescribe an FDA-approved drug.
- Maximize lifestyle modification and non-pharmacologic therapies.
Drs. Robert Kushner and Gordon Schiff argue for each approach. View article
|
|
Effects of a Meal Replacement System Alone or in Combination with Phentermine on Weight Loss and Food Cravings
Moldovan, C. P., et al. Obesity, 2016.
A 12-week study was conducted to examine the effects of phentermine combined with a meal replacement program on weight loss and food cravings. Seventy-seven adults with obesity received either phentermine or placebo. All were provided meal replacements, were instructed to follow a structured eating plan for weight loss, and received lifestyle coaching. Results showed that the phentermine group lost 12.1% of baseline body weight compared with 8.8% in the placebo group. Cravings for all food groups decreased in both groups; however, there was a greater reduction in cravings for fats and sweets in the phentermine group compared with the placebo group. Percent weight loss was related to reduced total food cravings and specifically for sweets. These findings suggest that phentermine may enhance the effects of a meal-replacement program, possibly due to its effects on food cravings. View article
|
|
Does Basal Metabolic Rate Predict Weight Gain?
Anthanont, P., and Jensen, M. D. AJCN, 2016.
Previous studies suggest that low basal metabolic rate (BMR) may be an independent predictor of future weight gain. A study was conducted to assess whether adults (n=163) with a low BMR gain more weight than do adults with a high BMR who are living in a typical Western environment. Results showed that when high BMR was compared to low BMR, there was no difference in rates of weight gain over the ~9.7 year follow-up period. These findings imply that habitual differences in food intake or activity offset variations in BMR as a risk factor for weight gain. View article
|
Pediatric Obesity Research Update
|
|
Pediatric obesity research updates are brought to you by the pediatric committee. This month's article was written by Dr. Sara Karjoo.
|
Administration of Antibiotics to Children before Age 2 Years Increases Risk for Childhood Obesity
Scott, F. I., et al. Gastroenterology 2016.
Dysbiosis, or alternations of the microbiota, have been studied and suspected to be one risk factor for the development of obesity. This study was a retrospective population-based cohort study assessing the association between antibiotic exposure before age 2 and subsequent risk and development of obesity at age 4. Patient data from 1995-2013 was accessed from the U.K. Health Improvement Network (THIN). THIN is a data set generated by participating general practitioners in the U.K.; it represents 6 percent of the population. Children from 3 months to 2 years of age were identified. Data was collected up to 4 years of age. The height and weight was recorded, and the outcome measure was obesity based on World Health Organization BMI z-scores at 4 years of age. Obesity was identified as a BMI greater than or equal to 2.37 for males and BMI greater than or equal to 2.25 for females. Also recorded were the types of antibiotics used and the age of first exposure, as well as birth month, geographic region, mode of delivery, socioeconomic status, obesity as an infant, maternal diabetes, and family history of obesity. A total of 1,306 patients were identified to have obesity by age 4, met the inclusion criteria, and were assessed for this study. Read more or view article
|
|
Join Us Next Spring: Obesity Medicine 2017 Is in Seattle from April 19-23!
We are excited to announce our upcoming conference, Obesity Medicine 2017 will be held in Seattle. Attend Obesity Medicine 2017 to gain practical knowledge on implementing the four treatment pillars, prepare for the ABOM certification exam, and gain a broader understanding of obesity and obesity-related conditions. Register online now! |
Review Course for the ABOM Exam (April 19-20)
Addresses the clinical topics physicians need to know for the American Board of Obesity Medicine (ABOM) certification exam.
|
Essentials for Building a Sustainable Obesity Medicine Practice (April 19-20)
Focuses on essential topics to help you build and grow a sustainable obesity medicine practice.
|
Spring Obesity Summit (April 21-23)
Offers you practical strategies for a wide range of patient cases and obesity-related conditions you may encounter in practice.
|
|
|
|
|
The Obesity Medicine Association and the Obesity Treatment Foundation thank our 2016 Corporate Advisory Council members for their continuous support.
|
© 2016 Obesity Medicine Association. All rights reserved. Materials may not be reproduced, redistributed or translated without written permission. Advertising disclaimer: Under a policy approved by the OMA executive committee and exhibitor/advertiser review committee, commercial companies may apply to advertise in OMA publications. Approval does not imply endorsement or official recognition of particular products or services.
|
|
|
|
